CUBE LABS: CARTILAGO SECURES 2nd U.S. PATENT FOR REGENERATIVE OSTEOARTHRITIS THERAPIES
Other patent applications are pending in Europe, China, and Japan.
Rome, September 16, 2024 – Cube Labs S.p.A. (referred to as “Cube Labs” or the “Company”), an Italian healthcare technology venture builder listed on Euronext Growth Milan, announced that the U.S. Patent and Trademark Office (USPTO) has granted Cartilago, a clinical-stage regenerative medicine startup founded and controlled by Cube Labs, its second patent.
Issued on September 10, 2024, under patent number US 12,084,471, this new patent complements the one issued in June 2023 (No. US 11,685,760). It covers injectable solutions of regenerative dermal and chondroprotective molecules developed by Cartilago. This patent enhances the company’s broad-spectrum protection for osteoarthritis applications and related conditions in a key market, further strengthening its intellectual property portfolio.
Filippo Surace, CEO and founder of Cube Labs, said: “This second patent is a significant milestone for Cartilago, as it extends vital protection for our innovative disease-modifying technologies in osteoarthritis and dermal regeneration, specifically regarding injectable administration, and allows us to move toward commercialization.”
This patent belongs to Cartilago’s second patent family, which focuses on technologies for developing therapies targeting osteoarthritis and related conditions. These therapies stimulate the production of new cartilage, extracellular matrix generation, collagen production, and endogenous hyaluronic acid production. Additional patent applications are underway in Europe, China, and Japan.
Cartilago’s leading technology pipeline includes a transformative and disease-modifying treatment for osteoarthritis. In November 2022, the company also announced clinical study results confirming the effectiveness of its proprietary molecule, Regen Longevity, in reducing periorbital wrinkles.
Cube Labs
Cube Labs, Italy’s premier venture builder in healthcare technology, bridges the gap between cutting-edge academic research and the global life sciences market. The company is dedicated to translating scientific discoveries into impactful, real-world healthcare solutions, and is committed to democratizing life sciences to foster a healthier and more inclusive world. Aligned with the United Nations’ 2030 Agenda for Sustainable Development Goals, Cube Labs collaborates with global communities interested in innovation to enhance patient outcomes and accelerate the transition to optimal health. Cube Labs S.p.A is listed on the Italian Stock Exchange, Euronext Growth Milan – Professional Segment.
Global Media Contact
Isil Guney
Tel: +90 5325027243
E-mail: i.guney@cube-labs.com
Ufficio Stampa Italia di Cube Labs
SEC and Partners
Matteo Steinbach
Cell. +393461063989
E-mail: matteo.steinbach@secnewgate.it
Federico Ziglioli
Cell. +393331225959
E-mail: federico.ziglioli@secnewgate.it